Other languages Nuvectis Pharma, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-12 EDT			5-day change	1st Jan Change
6.65 ^USD	+0.30%		+9.20%	-20.26%

05-07	Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	CI

Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	04-08
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer	03-14
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Nuvectis Pharma Starts Phase 1a Trial of NXP900 in Solid Tumors	23-09-12
Nuvectis Pharma, Inc. Announces Initiation of the NXP900 Phase 1a Clinical Trial	23-09-12
Nuvectis Pharma's NXP800 Cholangiocarcinoma Treatment Candidate Gets US FDA Orphan Drug Label	23-08-17
Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Insider Buy: Nuvectis Pharma	23-07-27
Insider Buy: Nuvectis Pharma	23-07-24
Insider Buy: Nuvectis Pharma	23-07-20
Insider Buy: Nuvectis Pharma	23-07-19
Insider Buy: Nuvectis Pharma	23-07-12
Insider Buy: Nuvectis Pharma	23-07-10
Insider Buy: Nuvectis Pharma	23-06-27
Insider Buy: Nuvectis Pharma	23-06-20
Insider Buy: Nuvectis Pharma	23-06-16
Nuvectis Pharma Says US FDA Cleared Investigational New Drug Application for Oncology Drug Candidate NXP900	23-05-15
Nuvectis Pharma Inc. Announces FDA Clearance of NXP900 IND	23-05-15

No results for this search